HPV Prevalence in Colombian Women with Cervical Cancer: Implications for Vaccination in a Developing Country

Infectious Diseases in Obstetrics and Gynecology

Volumn 2009, Issue , 2009, Pages

  Murillo, Rúal ^a   Molano, Mnica ^a   Martínez, Gilberto ^b   Mejía, Juan Carlos ^a   Gamboa, Oscar ^a  

^a Instituto Nacional de Cancerología   (Colombia)

^b Clínica del Country de Bogotá   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; COLOMBIA; CONDYLOMA ACUMINATUM; DEVELOPED COUNTRY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VACCINATION; VIRUS DETECTION; WART VIRUS; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; GENETICS; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COLOMBIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; STATISTICS, NONPARAMETRIC; UTERINE CERVICAL NEOPLASMS;

EID: 75149126090     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/2009/653598     Document Type: Article

References (28)

1. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 CA: A Cancer Journal for Clinicians 2005 55 2 74 108
2. Walboomers J. M. M., Jacobs M. V., Manos M. M., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide Journal of Pathology 1999 189 1 12 19
3. Franco E. L., Tsu V., Herrero R., Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean Vaccine 2008 26 supplement 11 L88 L95
4. Villa L. L., Costa R. L. R., Petta C. A., High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up British Journal of Cancer 2006 95 11 1459 1466
5. Harper D. M., Franco E. L., Wheeler C. M., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial The Lancet 2006 367 9518 1247 1255
6. Clifford G., Franceschi S., Diaz M., Muoz N., Villa L. L., Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases Vaccine 2006 24 supplement 3 S26 S34
7. Agosti J. M., Goldie S. J., Introducing HPV vaccine in developing countrieskey challenges and issues The New England Journal of Medicine 2007 356 19 1908 1910
8. Goldie S. J., Diaz M., Constenla D., Alvis N., Andrus J. K., Kim S.-Y., Mathematical models of cervical cancer prevention in Latin America and the Caribbean Vaccine 2008 26 supplement 11 L59 L72
9. Clifford G. M., Smith J. S., Plummer M., Muoz N., Franceschi S., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis British Journal of Cancer 2003 88 1 63 73
10. Schiller J. T., Castellsagu X., Villa L. L., Hildesheim A., An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results Vaccine 2008 26 supplement 10 K53 K61
11. Pieros M., Ferlay J., Murillo R., Cancer incidence estimates at the national and district levels in Colombia Salud Publica de Mexico 2006 48 6 455 465
12. Murillo R., Pieros M., Hernndez G., Atlas de Mortalidad por Cncer en Colombia 2004 Bogot, Colombia Instituto Nacional de Cancerologa-Instituto Geogrfico Agustn Codazzi
13. Tavassoli F. A., Ville V., WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs 2003 Lyon, France IARC Press
14. de Roda Husman A. M., Walboomers J. M. M., Hopman E., HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern Journal of Medical Virology 1995 46 2 97 102
15. Jacobs M. V., Snijders P. J. F., van den Brule A. J. C., Helmerhorst T. J. M., Meijer C. J. L. M., Walboomers J. M. M., A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings Journal of Clinical Microbiology 1997 35 3 791 795
16. van den Brule A. J. C., Pol R., Fransen-Daalmeijer N., Schouls L. M., Meijer C. J. L. M., Snijders P. J. F., GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes Journal of Clinical Microbiology 2002 40 3 779 787
17. Muoz N., Bosch F. X., Castellsagu X., Against which human papillomavirus types shall we vaccinate and screen? The international perspective International Journal of Cancer 2004 111 2 278 285
18. Srndal C., Swensson B., Wretman J., Model Assisted Survey Sampling 1997 New York, NY, USA Springer
19. Muoz N., Bosch F. X., de Sanjose S., Epidemiologic classification of human papillomavirus types associated with cervical cancer The New England Journal of Medicine 2003 348 6 518 527
20. Smith J. S., Lindsay L., Hoots B., Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update International Journal of Cancer 2007 121 3 621 632
21. Bosch F. X., Burchell A. N., Schiffman M., Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia Vaccine 2008 26 supplement 10 K1 K16
22. Qu W., Jiang G., Cruz Y., PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems Journal of Clinical Microbiology 1997 35 6 1304 1310
23. Paavonen J., Jenkins D., Bosch F. X., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial The Lancet 2007 369 9580 2161 2170
24. Lpez-Revilla R., Martnez-Contreras L. A., Snchez-Garza M., Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma Infectious Agents and Cancer 2008 3, article 3
25. Santos C., Muoz N., Klug S., HPV types and cofactors causing cervical cancer in Peru British Journal of Cancer 2001 85 7 966 971
26. Roln P. A., Smith J. S., Muoz N., Human papillomavirus infection and invasive cervical cancer in Paraguay International Journal of Cancer 2000 85 4 486 491
27. Harper D. M., Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials Therapy 2008 5 3 313 324
28. Stanley M., Gissmann L., Nardelli-Haefliger D., Immunobiology of human papillomavirus infection and vaccinationimplications for second generation vaccines Vaccine 2008 26 supplement 10 K62 K67